Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports
Published in: Current Obesity Reports 3/2015

01-09-2015 | Health Services and Programs (SFL Kirk, Section Editor)

An Overview of Links Between Obesity and Mental Health

Authors: Christian Avila, Alison C. Holloway, Margaret K. Hahn, Katherine M. Morrison, Maria Restivo, Rebecca Anglin, Valerie H. Taylor

Published in: Current Obesity Reports | Issue 3/2015

Login to get access

Abstract

The American Medical Association recently recognized obesity as both an illness and a leading cause of preventable death and chronic disease. This association is not only linked to physical health outcomes, however, as obesity has also been extensively associated with mental illness as well. Both obesity and severe mental illness decrease quality of life and are associated with an increase in disability, morbidity, and mortality, and when they occur together, these adverse health outcomes are magnified. Despite educational campaigns, increased awareness, and improved treatment options, the high prevalence of mental illness and comorbid obesity remains a serious problem. This review examines this overlap, highlighting clinical and biological factors that have been linked to this association in order to improve our understanding and help elucidate potential therapeutic avenues.
Literature
1.
2.
Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA. 2004;291:2847–50.PubMedCrossRef
3.
Gadalla TM. Association of obesity with mood and anxiety disorders in the adult general population. Chronic Dis Can. 2009;30(1):29–36.PubMed
4.
Vanasse A, Demers M, Hemiari A, et al. Obesity in Canada: where and how many? Int J Obes. 2006;30:677–83.CrossRef
5.
Wilborn C, Beckham J, Campbell B, et al. Obesity: prevalence, theories, medical consequences, management, and research directions. J Int Soc Sports Nutr. 2005;2:4–31.PubMedCentralPubMedCrossRef
6.
7.
Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013;11(9):639–47.PubMedCrossRef
8.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Fifth ed.). Arlington: American Psychiatric Publishing; 2013. p. 5–25.
9.
Ferrari AJ, Norman RE, Freedman G, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. PLoS One. 2014;9(4):e91936.PubMedCentralPubMedCrossRef
10.
Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-47, HHS Publication No. (SMA) 13-4805. Rockville: Substance Abuse and Mental Health Services Administration; 2013. http://​store.​samhsa.​gov/​home.
11.
Kivimäki M, Batty GD, Singh-Manoux A, et al. Association between common mental disorder and obesity over the adult life course. Br J Psychiatry. 2009;195(2):149–55.PubMedCentralPubMedCrossRef
12.
13.
Cameron AJ, Magliano DJ, Dunstan DW, et al. A bi-directional relationship between obesity and health-related quality of life: evidence from the longitudinal AusDiab study. Int J Obes (Lond). 2012;36(2):295–303.CrossRef
14.
De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77.
15.
Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry. 2006;163(7):1132–4.PubMedCrossRef
16.
17.
Fliers EA, Buitelaar JK, Maras A, et al. ADHD is a risk factor for overweight and obesity in children. J Dev Behav Pediatr. 2013;34(8):566–74.PubMedCrossRef
18.
Pagoto SL, Curtin C, Lemon SC, et al. Association between adult attention deficit/hyperactivity disorder and obesity in the US population. Obesity. 2009;17(3):539–44.PubMedCentralPubMedCrossRef
19.•
Taylor VH, McIntyre RS, Remington G, et al. Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Can J Psychiatry. 2012;57(1):5–12. This review elucidate the complex interplay between psychiatric illness and weight gain.PubMed
20.
Cook BG, Li D, Heinrich KM. Obesity, physical activity, and sedentary behavior of youth with learning disabilities and ADHD. J Learn Disabil. 2014.
21.
Harvey WJ, Reid G, Grizenko N, et al. Fundamental movement skills and children with attention-deficit hyperactivity disorder: peer comparisons and stimulant effects. J Abnorm Child Psychol. 2007;35(5):871–82.PubMedCrossRef
22.
Harvey WJ, Reid G, Bloom GA, et al. Physical activity experiences of boys with and without ADHD. Adapt Phys Act Q. 2009;26:131–50.
23.
Cortese S, Angriman M, Maffeis C, et al. Attention deficit/hyperactivity disorder (ADHD) and obesity: a systematic review of the literature. Crit Rev Food Sci Nutr. 2008;48(6):524–37.PubMedCrossRef
24.
Levitan RD, Masellis M, Lam RW, et al. Childhood inattention and dysphoria and adult obesity associated with the dopamine D4 receptor gene in overeating women with seasonal affective disorder. Neuropsychopharmacology. 2004;29(1):179–86.PubMedCrossRef
25.
Comings DE, Blum K. Reward deficiency syndrome: genetics aspects of behavioral disorders. Prog Brain Res. 2000;126:325–41.PubMedCrossRef
26.
Hudson JI, Lalonde JK, Berry JM, et al. Binge-eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry. 2006;63(3):313–9.PubMedCrossRef
27.
Stanford C, Tannock R. Obesity and ADHD: clinical and neurobiological implications. In: Behavioral neuroscience of attention deficit hyperactivity disorder and its treatment. Ed Springer; 2012.
28.
Ranjba S, Deng C. The association of antidepressant medication and body weight gain. Online J Health Allied Sci Mangalore South India. 2013;12:ISSN 0972-5997.
29.
Hall KS, Hoerster KD, Yancy WS Jr. Post-traumatic stress disorder, physical activity, and eating behaviors. Epidemiol Rev. 2015.
30.
Mitchell KS, Aiello AE, Galea S, et al. PTSD and obesity in the Detroit neighborhood health study. Gen Hosp Psychiatry. 2013;35(6):671–3.PubMedCrossRef
31.
Kubzansky LD, Bordelois P, Jun HJ, et al. The weight of traumatic stress: a prospective study of posttraumatic stress disorder symptoms and weight status in women. JAMA Psychiatry. 2014;71(1):44–51.PubMedCentralPubMedCrossRef
32.•
Maguen S, Madden E, Cohen B, et al. The relationship between body mass index and mental health among Iraq and Afghanistan veterans. J Gen Intern Med. 2013;28 Suppl 2:S563–70. This study evaluated almost 500.000 veterans exploring the relationship between body mass index and posttraumatic stress disorder over 3 years.PubMedCrossRef
33.
Smith TJ, White A, Hadden L, et al. Associations between mental health disorders and body mass index among military personnel. Am J Health Behav. 2014;38(4):529–40.PubMedCrossRef
34.
Babić R, Maslov B, Babić D, et al. The prevalence of metabolic syndrome in patient with posttraumatic stress disorder. Psychiatr Danub. 2013;25 Suppl 1:45–50.PubMed
35.
Roenholt S, Beck NN, Karsberg SH, et al. Post-traumatic stress symptoms and childhood abuse categories in a national representative sample for a specific age group: associations to body mass index. Eur J Psychotraumatol. 2012;3(17188):1–9.
36.
Williamson DF, Thompson TJ, Anda RF, et al. Body weight and obesity in adults and self-reported abuse in childhood. Int J Obes Relat Metab Disord. 2002;26(8):1075–82.PubMedCrossRef
37.
D’Argenio A, Mazzi C, Pecchioli L, et al. Early trauma and adult obesity: is psychological dysfunction the mediating mechanism? Physiol Behav. 2009;98(5):543–6.PubMedCrossRef
38.
39.
de Assis MA, de Mello MF, Scorza FA, et al. Evaluation of physical activity habits in patients with posttraumatic stress disorder. Clinics (Sao Paulo). 2008;63(4):473–8.CrossRef
40.
Hirth JM, Rahman M, Berenson AB. The association of posttraumatic stress disorder with fast food and soda consumption and unhealthy weight loss behaviors among young women. J Womens Health (Larchmt). 2011;20(8):1141–9.CrossRef
41.
Russell E, Koren G, Rieder M, et al. Hair cortisol as a biological marker of chronic stress:current status, future directions and unanswered questions. Psychoneuroendocrinology. 2012;37(5):589–601.PubMedCrossRef
42.
Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007;13(7):803–11.PubMedCrossRef
43.
Mason SM, Flint AJ, Roberts AL, et al. Posttraumatic stress disorder symptoms and food addiction in women by timing and type of trauma exposure. JAMA Psychiatry. 2014;71:1271–8.PubMedCrossRef
44.
Weiner M, Warren L, Fiedorowickz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1):40–7.PubMedCentralPubMed
45.
Opel N, Redlich R, Grotegerd D, et al. Obesity and major depression: body-mass index (BMI) is associated with a severe course of disease and specific neurostructural alterations. Psychoneuroendocrinology. 2015;51:219–26.PubMedCrossRef
46.
Liu CS, Carvalho AF, McIntyre RS. Towards a “metabolic” subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10):1693–707.PubMedCrossRef
47.
Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry. 2006;67(7):1034–41.PubMedCrossRef
48.
Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54(3):317–29.PubMedCrossRef
49.
Mansur RB, Brietzke E, McIntyre RS. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015.
50.
Brumby S, Chandrasekara A, Kremer P, et al. The effect of physical activity on psychological distress, cortisol and obesity: results of the Farming Fit intervention program. BMC Public Health. 2013;13:1018.PubMedCentralPubMedCrossRef
51.
52.
Shelton RC, Miller AH. Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci. 2011;13(1):41–53.PubMed
53.
Palinkas LA, Wingard DL, Barrett-Connor E. Depressive symptoms in overweight and obese older adults: a test of the ‘jolly fat’ hypothesis. J Psychosom Res. 1996;40:59–66.PubMedCrossRef
54.
Lago F, Dieguez C, Gómez-Reino J, et al. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007;3(12):716–24.PubMedCrossRef
55.
Degawa-Yamauchi M, Moss KA, Bovenkerk JE, et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res. 2005;13(4):662–9.PubMedCrossRef
56.
Taylor VH, MacQueen GM. The role of adipokines in understanding the associations between obesity and depression. J Obes. 2010;2010.
57.
De Wit L, Luppino F, van Straten A, et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010;178(2):230–5.PubMedCrossRef
58.
Soczynska JK, Kennedy SH, Woldeyohannes O, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med. 2011;13:93–116.CrossRef
59.
Dent R, Blackmore A, Peterson J, et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One. 2012;7(6):e36889.PubMedCentralPubMedCrossRef
60.
Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord. 2014;169S1:S34–44.CrossRef
61.
62.
63.
Hsu WY, Lane HY, Lin CL, et al. A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients. Schizophr Res. 2015;162(1–3):248–52.PubMedCrossRef
64.
Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. Clin Psychiatry. 2002;63 suppl 9:5–11.
65.
Jeste DV, Gladsjo JA, Lindamer LA, et al. Medical comorbidity in schizophrenia. Schizophr Bull. 1996;22:412–30.CrossRef
66.
Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64–6.PubMedCrossRef
67.
Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry. 2006;14(4):212–22.PubMedCrossRef
68.
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1–93.PubMed
69.
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–25.PubMedCrossRef
70.
Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537–43.PubMedCrossRef
71.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–73.PubMedCentralPubMedCrossRef
72.
Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, Hetrick S, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008;22(7):547–62.PubMedCrossRef
73.
74.
Britvic D, Maric NP, Doknic M. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review. Psychiatr Danub. 2013;25(4):410–5.PubMed
75.
76.
Lencz T et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010;20:569–72.PubMedCentralPubMedCrossRef
77.
Cowley MA, Cone R, Enriori P, et al. Electrophysiological actions of peripheral hormones on melanocortin neurons. Ann N Y Acad Sci. 2003;994:175–86.PubMedCrossRef
78.
Zhou L, Williams T, Lachey JL, et al. Serotonergic pathways converge upon central melanocortin systems to regulate energy balance. Peptides. 2005;26(10):1728–32. Review.PubMedCrossRef
79.
Taveira TH, Wu WC, Tschibelu E, et al. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study. J Psychopharmacol. 2014;28(4):395–400.PubMedCrossRef
80.
Nothdurfter C, Schmotz C, Sarubin N, et al. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness. J Psychiatr Res. 2014;52:15–20.PubMedCrossRef
81.
De Silva PN. Does the association with diabetes say more about schizophrenia and its treatment?--the GLUT hypothesis. Med Hypotheses. 2011;77(4):529–31.PubMedCrossRef
82.
Chintoh AF, Mann SW, Lam L, et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res. 2009;108(1–3):127–33.PubMedCrossRef
83.
Hahn M, Chintoh A, Giacca A, et al. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res. 2011;131(1–3):90–5.PubMedCrossRef
84.•
Ballon JS, Pajvani U, Freyberg Z, et al. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014;25(11):593–600. This manuscript describes antipsychotics putative mechanisms on weight gain as well as metabolic risks of schizophrenia itself.PubMedCrossRef
85.
Stone WS, Faraone SV, Su J, et al. Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am J Med Genet B Neuropsychiatr Genet. 2004;127B(1):5–10.PubMedCrossRef
86.
Sahoo S, Ameen S, Akhtar S. Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics. Aust N Z J Psychiatry. 2007;41(7):629.PubMed
87.
88.
De Domingo Bartolomé M, López Guzmán J. The social stigma of obesity. Cuad Bioet. 2014;25(84):273–84.PubMed
89.
90.
91.
Manasse SM, Forman EM, Ruocco AC, et al. Do executive functioning deficits underpin binge eating disorder? A comparison of overweight women with and without binge eating pathology. Int J Eat Disord. 2015.
92.
Mauro M, Taylor V, Wharton S, et al. Barriers to obesity treatment. Eur J Intern Med. 2008;19(3):173–80.PubMedCrossRef
93.
94.
Swinburn BA, Caterson I, Seidell JC, et al. Diet, nutrition and the prevention of excess weight gain and obesity. Public Health Nutr. 2004;7:123–46.PubMed
95.
Fairburn C, Brownell K. Eating disorders and obesity: a comprehensive handbook. 2002.
96.
Schreiber LR, Odlaug BL, Grant JE. The overlap between binge eating disorder and substance use disorders: diagnosis and neurobiology. J Behav Addict. 2013;2(4):191–8.PubMedCentralPubMedCrossRef
97.
Goracci A, Casamassima F, Iovieno N, et al. Binge eating disorder: from clinical research to clinical practice. J Addict Med. 2015;9(1):20–4.PubMedCrossRef
Metadata
Title
An Overview of Links Between Obesity and Mental Health
Authors
Christian Avila
Alison C. Holloway
Margaret K. Hahn
Katherine M. Morrison
Maria Restivo
Rebecca Anglin
Valerie H. Taylor
Publication date
01-09-2015
Publisher
Springer US
Published in
Current Obesity Reports / Issue 3/2015
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-015-0164-9

Other articles of this Issue 3/2015

Current Obesity Reports 3/2015 Go to the issue

The Obesity Epidemic: Causes and Consequences (A Peeters and S Tanamas, Section Editors)

A Review of the Relationship Between Socioeconomic Position and the Early-Life Predictors of Obesity

The Obesity Epidemic: Causes and Consequences (A Peeters and S Tanamas, Section Editors)

How Can We Better Prevent Obesity in Children?

Health Services and Programs (SFL Kirk, Section Editor)

Ethical Issues for Public Health Approaches to Obesity

Health Services and Programs (SFL Kirk, Section Editor)

Social Entrepreneurship for Obesity Prevention: What Are the Opportunities?

Health Services and Programs (SFL Kirk, Section Editor)

Obesity Genes, Personalized Medicine, and Public Health Policy

The Obesity Epidemic: Causes and Consequences (A Peeters and S Tanamas, Section Editors)

The Double Burden of Undernutrition and Overnutrition in Developing Countries: an Update
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits